{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:22:29Z","timestamp":1783736549856,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.contraception.2011.09.010","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T14:27:52Z","timestamp":1323440872000},"page":"437-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg\/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome"],"prefix":"10.1016","volume":"85","author":[{"given":"Ellen W.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uriel","family":"Halbreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Grubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Rapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven O.","family":"Skouby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger D.","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.09.010_bb0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-1781(96)02929-0","article-title":"Reliability and validity of a daily diary for premenstrual syndrome","volume":"65","author":"Freeman","year":"1996","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.contraception.2011.09.010_bb0010","first-page":"771","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.contraception.2011.09.010_bb0015","first-page":"1","article-title":"ACOG practice bulletin: premenstrual syndrome","volume":"15","author":"American College of Obstetricians and Gynecologists","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1034\/j.1600-0447.2001.00412.x","article-title":"The epidemiology of perimenstrual psychological symptoms","volume":"104","author":"Angst","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.contraception.2011.09.010_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S0033291701004925","article-title":"Prevalence, incidence, and stability of premenstrual dysphoric disorder in the community","volume":"32","author":"Wittchen","year":"2002","journal-title":"Psychol Med"},{"key":"10.1016\/j.contraception.2011.09.010_bb0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1067\/mob.2000.106580","article-title":"Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study","volume":"183","author":"Spitzer","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-0327(01)00458-X","article-title":"Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles","volume":"70","author":"Cohen","year":"2002","journal-title":"J Affect Disord"},{"issue":"Suppl 3","key":"10.1016\/j.contraception.2011.09.010_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0306-4530(03)00099-4","article-title":"Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis","volume":"28","author":"Freeman","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.contraception.2011.09.010_bb0045","first-page":"30","article-title":"Premenstrual dysphoric disorder: recognition and treatment","volume":"5","author":"Freeman","year":"2003","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.contraception.2011.09.010_bb0050","first-page":"1","article-title":"The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS\/PMDD)","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.contraception.2011.09.010_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3949\/ccjm.71.4.303","article-title":"Premenstrual dysphoric disorder: a review for the treating practitioner","volume":"71","author":"Kaur","year":"2004","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.contraception.2011.09.010_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jom.0000150209.44312.d1","article-title":"Estimating direct and indirect costs of premenstrual syndrome","volume":"47","author":"Borenstein","year":"2005","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.contraception.2011.09.010_bb0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.jom.0000131796.62115.84","article-title":"A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome","volume":"46","author":"Dean","year":"2004","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.contraception.2011.09.010_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/15246090152543148","article-title":"Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder","volume":"10","author":"Freeman","year":"2001","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1016\/j.contraception.2011.09.010_bb0080","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.09.010_bb0085","first-page":"CD006586","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","author":"Lopez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2011.09.010_bb0090","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(02)00445-6","article-title":"Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial","volume":"67","author":"Kwiecien","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.09.010_bb0100","first-page":"653","article-title":"Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial","volume":"101","author":"Miller","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0105","unstructured":"LYBREL\u00ae (90 mcg levonorgestrel and 20 mcg ethinyl estradiol) prescribing information. Pfizer Inc."},{"key":"10.1016\/j.contraception.2011.09.010_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2011.05.008","article-title":"Continuous oral levonorgestrel\/ethinyl estradiol for treating premenstrual dysphoric disorder","author":"Halbreich","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.09.010_bb0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2006.07.005","article-title":"Evaluation of a continuous regimen of levonorgestrel\/ethinyl estradiol: phase 3 study results","volume":"74","author":"Archer","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.09.010_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00737-005-0103-y","article-title":"Daily Record of Severity of Problems (DRSP): reliability and validity","volume":"9","author":"Endicott","year":"2006","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.contraception.2011.09.010_bb0125","first-page":"9","article-title":"The work limitations questionnaire","volume":"28","author":"Lerner","year":"2002","journal-title":"Quality of Life Newsletter"},{"key":"10.1016\/j.contraception.2011.09.010_bb0130","first-page":"13","article-title":"Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects","volume":"33","author":"Endicott","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.contraception.2011.09.010_bb0135","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology, revised edition. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"10.1016\/j.contraception.2011.09.010_bb0140","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jama.1997.03550120043031","article-title":"Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial","volume":"278","author":"Yonkers","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.09.010_bb0145","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/archpsyc.56.10.932","article-title":"Differential response to antidepressants in women with premenstrual syndrome\/premenstrual dysphoric disorder. A randomized controlled trial","volume":"56","author":"Freeman","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.contraception.2011.09.010_bb0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4088\/JCP.v61n0205","article-title":"Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo","volume":"61","author":"Pearlstein","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.contraception.2011.09.010_bb0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jad.2004.10.006","article-title":"Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase","volume":"85","author":"Yonkers","year":"2005","journal-title":"J Affect Disord"},{"key":"10.1016\/j.contraception.2011.09.010_bb0160","first-page":"435","article-title":"Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries","volume":"100","author":"Cohen","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0165","first-page":"737","article-title":"Venlafaxine in the treatment of premenstrual dysphoric disorder","volume":"98","author":"Freeman","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.09.010_bb0170","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411005294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411005294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:09:44Z","timestamp":1762117784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411005294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0010782411005294"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.09.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg\/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}